A Phase 2 interventional study of LXH254 and LTT462 in Melanoma, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 36 sites in 12 countries. Open to participants aged 12 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
How we know · 10 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing trametinib in Melanoma — 2 open to participants now, 10 under way, none of them phase 3. trametinib · Melanoma.
Among the 46 studies testing trametinib in Melanoma, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 25 in phase 2, and was the 44th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →2 of the 46 studies testing trametinib in Melanoma are open now, in 12 countries. Recruiting first, the newest first:
Inge Marie Svane · Sites in Denmark
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 12 more countries
Ages 18–100
By country, each count listing its studies:
trametinib: first FDA approval 2013 (MEKINIST), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 12 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 30 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 47 across the 46 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
51 studies in Melanoma by Novartis: 1 open now, 6 under way, none of them phase 3. Of 43 finished, 18 (42%) have results posted.
Among the 51 studies in Melanoma by Novartis, this one is the 18th largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2020, is one of 10 in phase 2, and was the 33rd registered.
Novartis’s Melanoma studies by the year they started, since 1998.
2 of the studies testing trametinib in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04417621Novartis PharmaceuticalsStudy of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | 2027-02-02 |
| NCT02231775M.D. Anderson Cancer CenterDabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing trametinib in Melanoma, from their registry updates:
Among Novartis’s 51 in Melanoma:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female must be ≥ 12 years For adolescents only (12-17 years): body weight > 40kg confirmed unresectable or cutaneous melanoma
Previously treated for unresectable or metastatic melanoma:
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:
Participants participating in additional parallel investigational drug or medical device studies.
All primary central nervous system (CNS) tumors or symptomatic that are neurologically unstable History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).
Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Other protocol-defined exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LXH254 · Drug: LTT462
Drug: Trametinib
Drug: Ribociclib
LXH254 will be supplied as tablet for oral use.
LTT462 will be supplied as hard gelatin capsule for oral use.
Trametinib will be supplied as film-coated tablet for oral use
Ribociclib will be supplied in tablets and hard gelatin capsules.
Overall Response Rate
Confirmed ORR using RECIST v1.1, per local assessment
Time frame: 35 months
Duration of Reposnse (DOR)
Local and central assessment
Time frame: 4 years
Progression Free Survival (PFS)
Time frame: 4 years
Disease Control Rate (DCR)
Using RECIST v1.1, per local and central assessment
Time frame: 3 years
Overall Survival (OS)
Time frame: 4 years
Derived PK parameter (Cmax) for LXH254 & LTT462
Time frame: Up to 5 months
Derived PK parameter (Cmax) for LXH254 & trametinib
Time frame: Up to 5 months
Derived PK parameter (Cmax) for LXH254 & ribociclib
Time frame: Up to 5 months
Derived PK parameter (AUC) for LXH254 & LTT462
Time frame: Up to 5 months
Derived PK parameter (AUC) for LXH254 & trametinib
Time frame: Up to 5 months
Derived PK parameter (AUC) for LXH254 & ribociclib
Time frame: Up to 5 months
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Number of participants with Adverse Events (AEs) and SAEs as a measure of safety and tolerability
Time frame: 35 months
Dose Interruptions
Tolerability measured by the number of subjects who have interruptions of study treatment and reason for interruptions
Time frame: 35 months
Dose reductions
Tolerability measured by the number of subjects who have reductions of study treatment and reason for reductions
Time frame: 35 months
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Started Oct 2020 (actual). Primary completion is estimated for Feb 2027, 75 months after the start.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 75 months is above that.
Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naporafenib · Trametinib